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Sex Med 2Introduction: Erectile dysfunction (ED) is a multidimensional disorder with an estimated prevalence of 1% to
10% in men younger than 40 years and up to 100% in men in their 70s and 80s.
Aim: To evaluate the real-life characteristics and unmet needs of men with ED, its impact on well-being, and
treatment rates across Europe.
Methods: Adult men in Belgium, France, Germany, Italy, Poland, Portugal, and Spain were invited to
participate in the survey. Men who did not use at least a drug for sexual health in the past 3 months, had cancer
or spinal cord injuries, and/or underwent nonenerve-sparing radical prostatectomy were excluded.
Main Outcome Measures: The 15-item International Index of Erectile Function (IIEF-15) with study-specific,
self-constructed questions was used.
Results: Overall, 940 subjects (age ¼ 46.2 ± 13.4 years) were considered. Subjects (n ¼ 778) using on-demand
phosphodiesterase type 5 inhibitors (PDE5is) were designated “performers” (60%) without a formal ED diag-
nosis or “patients” with a medical diagnosis. Patients were older than performers, with more self-reported
comorbidities; patients used a higher PDE5i dosage and purchased it from official pharmacies more often
than performers did. Of avanafil users (n ¼ 39), no differences in total IIEF or subdomain scores were observed
after adjusting for confounders. However, avanafil users less often declared its use without an ED diagnosis and a
physician prescription. Overall, the latter condition was associated with higher PDE5i-related satisfaction.
Conclusion: The survey shows 2 different attitudes toward ED and PDE5i use: for recreational use and without
a medical prescription or with a formal diagnosis and medical prescription. Avanafil, a 2nd-generation PDE5i
with a good balance between efficacy and tolerability profile, is more frequently prescribed by doctors than
self-prescribed compared with other PDE5is. Because the major challenge is to decrease the high dropout of
1st-generation PDE5is, further studies will be needed to clarify this topic. Corona G, Maggi M, Jannini EA.
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Erectile dysfunction (ED) is a multidimensional disorder with
an estimated prevalence ranging from 1% to 10% in men younger
than 40 years and up to 100% in men in their 70s and 80s, with
higher rates in the United States and Southeast Asia than in
Europe.1 ED is a potential predictor of cardiovascular diseases,
especially in younger and less complicated individuals2e6; it
negatively affects quality of life and fitness of the couple, thus
further worsening ED-associated cardiovascular risk.7e10 How-
ever, ED remains under-recognized, underdiagnosed, and15
16 Corona et alundertreated. In Italy in 2001, a large free-call information service
on ED with more than 16,000 phone contacts showed that up to
41% of men with severe ED for more than 3 years had never
sought medical help for their problems or discussed it with their
general physician.11
Since 1998, when sildenafil was 1st approved by the European
Medicine Agency (EMA), phosphodiesterase type 5 inhibitors
(PDE5is) have revolutionized the evaluation and treatment of ED
and improved awareness of the problem in the social and scientific
communities.12e15 1st-generation PDE5is—sildenafil, tadalafil,
and vardenafil—were effective in more than 80% of unselected
patients with ED.12 However, most men with ED do not
consider the problem serious or are too embarrassed to consult
physicians.16 A large web survey of more than 5,000 subjects
showed that approximately 50% of men with ED did not discuss
their condition with general physicians.16 Even when properly
diagnosed, ED treatment and follow-up are challenging. Despite
the high efficacy and easy administration of 1st-generation
PDE5is, the discontinuation rate and dissatisfaction are very high.
A recent meta-analysis indicated a mean discontinuation rate of
4% per month for 1st-generation PDE5is.17 Furthermore, almost
50% of men stopped their treatment with sildenafil, tadalafil, or
vardenafil within 1 year.17 In recent years, PDE5is became pop-
ular among men without ED as a recreational drug to improve
sexual performance.18 This behavior could lead to serious unex-
pected adverse effects, especially when PDE5is are used in com-
bination with alcohol, illicit drugs, and psychotropic medication
or in the presence of concomitant medical conditions.18
Approved by the EMA in 2013, avanafil is a 2nd-generation
PDE5i with similar efficacy but significantly fewer side effects
compared with 1st-generation compounds.14,15 A meta-analysis
of randomized studies showed that avanafil was up to 3-fold
superior to placebo in achieving successful sexual intercourse.14
However, few data on avanafil efficacy and safety in the real-
word setting are available.
This study evaluated real-life characteristics and unmet needs
of men with ED, its impact on men’s well-being, and rates of ED
treatment per age and European country. Health care resource
attitudes among men with ED were investigated.
METHODS
Sample and Recruitment
From November to December 2016, the Erectile Dysfunction
European Users Survey (EDEUS) was conducted with the
Computer Assisted Web Interviewing method in Belgium,
France, Germany, Italy, Poland, Portugal, and Spain. The survey
involved adults who belonged to an online market research
proprietary panel on “Men’s Health Condition” (https://it.
toluna.com/). Eligible participants had to be men, older than
18 years, sexually active, and to have used drugs for sexual male
health during the past 3 months. Men who had cancer, had
spinal cord injuries, or underwent nonenerve-sparing radical
prostatectomy were excluded.Informed consent was obtained from each subject registered to
the panel. Because of the non-interventional design of the online
survey, ethical approval was not mandatory.Material
The 15-item International Index of Erectile Function-15
(IIEF-15)19 and a set of study-specific, self-constructed ques-
tions were used to assess general health status, type and dosing of
PDE5i prescribed, and treatment expectations and further needs.
Questions were related to the previous 3 months. The ques-
tionnaire is available as Supplementary File 1.Statistical Analysis
Normally distributed data were reported as mean and SD, and
non-normally distributed data were expressed as median and
interquartile range. According to data distribution, 1-way anal-
ysis of variance or Kruskal-Wallis test was applied to detect dif-
ferences; Spearman or Pearson methods were used to estimate
correlations; and unpaired 2-sided Student t-test and Mann-
Whitney U-test were applied to compare groups. Multivariate
analyses were performed using stepwise multiple linear or logistic
regression models whenever appropriate. All statistical analysis
was performed with SPSS 21.1 for Windows (SPSS, Inc,
Chicago, IL, USA).RESULTS
Demographic Characteristics
From an initial panel of 359,160 subjects who were mailed the
survey, 30,905 started the survey. Of these, 3,315 (10.72%) did
not complete it and 26,650 (86.23%) did not meet the inclusion
criteria. Thus, a final population of 940 subjects was considered
for this analysis (eFigure 1).
The mean age was 46.2 years (SD ¼ 13.4), with a higher
prevalence of men 35 to 54 years old (Table 1). Most subjects
had mild-to-moderate or mild ED; based on IIEF results, more
than 15% did not self-report ED, although they stated they were
interested in ED treatment or erectile function improvement
(Table 1). Dyslipidemia and hypertension were the most com-
mon associated comorbidities. Among psychological symptoms,
anxiety and depression were reported by more than 20%
(Table 1). Heterosexual men were the clear majority, but more
than 10% were bisexual or homosexual (Table 1). Overall, 778
men (82.8%) reported the use of on-demand PDE5is. Sildenafil
was the most common PDE5i used, followed by tadalafil, var-
denafil, and avanafil (Table 1). To make the results more com-
parable, analysis was based only on subjects who reported
on-demand use of PDE5i (n ¼ 778).Medical Diagnosis
Of subjects who declared on-demand use of PDE5i, 40%
stated they had a medical diagnosis of ED (hereafter referred to
“patients”) and the remainder did not receive any formal medicalSex Med 2018;6:15e23
Table 1. Characteristics of entire sample
Total sample, N 940









Age (y), mean ± SD 46.2 ± 13.4




ED categories (according to IIEF), n (%)
Severe 77 (8.2)
Moderate 165 (17.6)
Mild to moderate 299 (31.8)
Mild 257 (27.3)
No ED 142 (15.1)
Associated comorbidities (>1 can
be present in the same patient), n (%)
Diabetes 171 (18.2)
Increased cholesterol 280 (29.8)
Increased blood pressure 256 (27.2)
Previous diagnosis of cardiac disease 82 (8.7)
Depression 196 (20.9)
Anxiety symptoms 233 (24.8)
Renal diseases 36 (3.8)
Hepatic diseases 32 (3.4)




Not answer 9 (1)
PDE5i used most often in past
month (single answer), n (%)
Sildenafil 404 (43)
Tadalafil on demand 244 (26)




ED ¼ erectile dysfunction; IIEF ¼ International Index of Erectile Function;
PDE5i ¼ phosphodiesterase type 5 inhibitor.
Users of Phosphodiesterase Type 5 Inhibitors 17ED diagnosis (hereafter referred to “performers”): 49% of these
subjects had self-diagnosed ED and 11% did not consider
themselves affected by ED (Table 2). Patients were older than
other men (49.2 ± 13.7 vs 46.3 ± 13.4 years; P ¼ .004),
whereas no differences were observed between subjects with a
self-diagnosis or without ED diagnosis (not shown). A higher
prevalence of diabetes mellitus was reported by patients (n ¼ 73Sex Med 2018;6:15e23of 309) than by performers (n ¼ 81 of 469; 23.6% vs 17.3%;
P ¼ .03). This association was confirmed after adjusting for age
(hazard ratio ¼ 1.51, 95% CI ¼ 1.06e2.16, P ¼ .024). No
statistically significant differences were reported for other
comorbidities (data not shown).
Patients rarely declared on-demand use of PDE5i at the lowest
dosing compared with performers; they used the PDE5i as pre-
scribed by physicians or other qualified health care practitioners
and more frequently purchased drugs in an official pharmacy
(Table 2). Performers mainly used the PDE5i as a recreational
drug and rarely to improve erection quality or to gratify their
partner; they reported self-prescription of drugs and purchased
them in official pharmacies less frequently than patients
(Table 2). Subjects who received a PDE5i prescription from
physicians or other qualified health care practitioners were more
often satisfied or highly satisfied with treatment (66.7 vs 58.3%;
P ¼ .027).
The main differences between patients and performers were
confirmed in a multivariate model after adjusting for age and
diabetes (Figure 1A). Similar results were observed when coun-
tries were introduced to the model as possible confounders (not
shown).Drug Dosage Use
Standard recommended dosages of PDE5i were used by 55%
of men (n ¼ 430), the lowest dosage was used by 25%
(n ¼ 191), and the highest dosage was used by 20% (n ¼ 157;
Table 3). Subjects who used the highest dosage were older
(52.1 ± 14.0 vs 46.3 ± 13.3 years; P ¼ .003) and with a longer
duration of ED and PDE5i use (5.4 ± 4.7 vs 4.2 ± 4.5 years,
P ¼ .008; 4.1 ± 3.1 vs 3.2 ± 3.0 years, P < .0001, respectively).
The prevalence of comorbidities was similar among groups
(not shown).
Concerning the reason for the use of PDE5i, subjects who
used the standard recommended dosage felt more relaxed during
sexual intercourse, whereas subjects who used the highest dosage
more often wanted to gratify their partner (Table 3). A larger
percentage of subjects using the lowest PDE5i dosage reported
recreational use of drugs, without statistical differences among
groups (Table 3).
Subjects who used the highest dosage more often reported
having a medical prescription and purchasing them in an official
pharmacy (Table 3), whereas those using the lowest dosage more
often reported a self-prescription and a PDE5i purchase from
online pharmacies (Table 3).
In a multivariate analysis, after adjusting for age, use of the
PDE5i at the highest dosage was still associated with a medical
prescription and with a purchase from official pharmacies
(Figure 1B). Similar results were observed when countries
were introduced to the model as possible further confounders
(not shown).
Table 2. Analysis for drug dosage, reason for taking PDE5i, advice to take PDE5i, and place used to buy PDE5i by diagnosis groups*
Question Category
Diagnosis groups (N ¼ 778), n (%)
No (n ¼ 88)
No, but I have some
problems (n ¼ 381) Yes (n ¼ 309)
Age (y), mean ± SD 46.9 ± 14.4 46.2 ± 13.2 49.2 ± 13.7
Drug dosage Low 26 (29.5)† 115 (30.2)§ 50 (16.2)
Standard 45 (51.1) 207 (54.3) 178 (57.6)
High 17 (19.3) 59 (15.5)‡ 81 (26.2)
Reason for taking PDE5i To improve strength and hardness
of erection
35 (39.8)§ 210 (55.1)†,k 202 (65.4)
To be more sure of myself 34 (38.6)† 200 (52.5)k 156 (50.5)
To gratify my partner 27 (30.7)‡ 165 (43.3)†,k 165 (53.4)
To feel more relaxed with my performance 33 (37.5) 144 (37.8) 125 (40.5)
To prevent performance anxiety 17 (19.3)† 130 (34.1)k 94 (30.4)
From curiosity; to try 9 (10.2)† 36 (9.4)‡ 9 (2.9)
Who decided to take or advised
taking PDE5i
Physician 37 (42.0)§ 204 (53.5)§ 278 (90.0)
Myself 35 (39.8)§ 112 (29.4)§ 17 (5.5)
Pharmacist 8 (9.1)† 38 (10.0)§ 7 (2.3)
Partner 5 (5.7) 24 (6.3)† 7 (2.3)
Place usually used to buy PDE5i Pharmacy 65 (73.9)‡ 289 (75.9)§ 274 (88.7)
Online pharmacy headquartered in
my country
13 (14.8) 67 (17.6)† 34 (11.0)
Online pharmacy headquartered abroad 9 (10.2) 36 (9.4) 19 (6.1)
Other (sex shop, disco, etc) 2 (2.3) 8 (2.1) 2 (0.6)
PDE5i ¼ phosphodiesterase type 5 inhibitor.
*1-way analysis of variance or Kruskal-Wallis test was applied to detect differences.
†P < .05; ‡P < .0005; §P < .0001 vs yes; kP < .05 vs no.
18 Corona et al1st- and 2nd-Generation PDE5i Users
Of subjects reporting on-demand use of PDE5is, 39 declared
using avanafil. Individuals using avanafil were similar to those
who used the 1st-generation drugs in age, ED duration, and
prevalence of comorbidities (Table 4). No difference between
avanafil and other PDE5i users were observed when considering
drug dosage group or reason for taking PDE5i (Table 4).
Subjects using avanafil rarely declared its use without an ED
problem and more often had a prescription from physicians
(Table 4).Figure 1. Panel A shows age- and self-reported diabetes-adjusted ass
of erectile dysfunction vs the rest of the sample. Panel B shows age
recommended dosage vs those using the lowest recommended dosagThe overall IIEF-15 score was similar in subjects who used
avanafil or other PDE5is (63.4 ± 17.0 vs 79.9 ± 9.7; P ¼ .45).
Avanafil was more frequently prescribed to subjects with severe
ED than other PDE5is (30.8% vs 7.0%; P < .0001). Subjects
using avanafil reported a lower IIEF-EF score (16.0 ± 7.2 vs
19.8 ± 5.8; P < .0001). This difference was not confirmed when
subjects with severe ED were excluded (IIEF-EF score ¼ 20.0 ±
4.4 vs 20.7 ± 4.6; P ¼ not significant; Figure 2). No differences
in other IIEF subdomains between subjects who used avanafil or
other PDE5is were observed (Figure 2).ociations between subjects who received a formal medical diagnosis
-adjusted associations between subjects using the highest PDE5i
e. PDE5i ¼ phosphodiesterase type 5 inhibitor.
Sex Med 2018;6:15e23
Table 3. Analysis for reason for taking PDE5i, advice to take PDE5i, and place used to buy PDE5i by drug dosage groups*
Question Category
Drug dosage groups (N ¼ 778), n (%)
High (n ¼ 157)
Standard
(n ¼ 430) Low (n ¼ 191)
Age (y), mean ± SD 52.1 ± 14.0 47.1 ± 12.9 44.5 ± 13.9
Reason for taking PDE5i To improve strength and hardness
of erection
97 (61.8) 248 (57.7) 102 (53.4)
To be more sure of myself 80 (51.0) 225 (52.3) 85 (44.5)
To gratify my partner 82 (52.2)† 200 (46.5) 75 (39.3)
To feel more relaxed with my performance 51 (32.5) 186 (43.3)†,k 65 (34.0)
To prevent performance anxiety 49 (31.2) 139 (32.3) 53 (27.7)
From curiosity, to try 6 (3.8) 31 (7.2) 17 (8.9)
Who decided to take or advised
taking PDE5i
Physician 118 (75.2)§ 300 (69.8)§ 101 (52.9)
Myself 26 (16.6)‡ 76 (17.7)§ 62 (32.5)
Pharmacist 6 (3.8)† 29 (6.7) 18 (9.4)
Partner 5 (3.2) 22 (5.1) 9 (4.7)
Place usually used to buy PDE5i Pharmacy 129 (82.2)† 364 (84.7)§ 135 (70.7)
Online pharmacy headquartered in
my country
22 (14.0) 53 (12.3)† 39 (20.4)
Online pharmacy headquartered abroad 16 (10.2) 30 (7.0) 18 (9.4)
Other (sex shop, disco, etc) 3 (1.9) 5 (1.2) 4 (2.1)
PDE5i ¼ phosphodiesterase type 5 inhibitor.
*1-way analysis of variance or Kruskal-Wallis test was applied to detect differences.
†P < .05; ‡P < .0005; §P < .0001 vs low; kP < .05 vs high.
Users of Phosphodiesterase Type 5 Inhibitors 19Of avanafil users, 20 (51.3%) stated they were satisfied or
highly satisfied; this percentage was similar to that reported by
subjects using the 1st-generation PDE5is (67.5%; P ¼ .93).
Data were not adequately powered to compare the prevalence of
satisfied patients between avanafil users who did and did not
receive a medical prescription.DISCUSSION
This real-life internet-based study described the perception of
ED as a medical symptom, the ability to discuss the problem
with physicians, and the aims in using these drugs in European
users. We distinguished 2 subgroups of PDE5i users: subjects
seeking a medical diagnosis (patients) and a large percentage of
users who did not receive a diagnosis or did not considered
themselves affected by ED (performers). The profile of each
subgroup is peculiar. Patients were older, with more self-reported
organic comorbidities or etiologies, and they were more likely to
purchase drugs in official pharmacies than performers. Patients
used these drugs mainly to improve erections and their partner’s
sexual life, whereas performers tried PDE5is for recreational use
and often purchased them online.
Since the National Institutes of Health Consensus Conference
on Impotence in 1992,20 the inadequate public and professional
understanding of ED started being addressed. However,
although numerous patient-oriented campaigns during the past
20 years have stressed the importance of considering ED aSex Med 2018;6:15e23medical symptom,11,21,22 a relatively large percentage of subjects
with an erectile concern (ie, performers) have not been interested
in seeking a medical and/or psycho-sexological diagnosis and a
medical prescription for these drugs. A survey involving 750
Mexican men with ED showed that only approximately half of
them sought treatment for this problem, which was more
frequently an alternative treatment than a pharmacologic
approach,23 although alternative treatments were surely less
effective than PDE5is.24 A study of 1,481 Dutch men indicated
that 67.3% were bothered by ED, 68.7% did not acknowledge
ED, and 85.3% sought help for ED. However, only 10.4% of
men with ED received medical care.25 Of 5,184 European men
who self-reported ED, more than 50% did not discuss their
condition with physicians, regardless of age.16 Therefore, high
barriers to discuss ED, erectile failures, or simply erectile con-
cerns are still present in a large part of the male population.
As we previously observed in another setting,16 we found that
patients were significantly older than performers, thus suggesting
that younger men are culturally less prone than older men to
acknowledge ED or an erectile concern as a medical symptom.
Main reasons for a delayed or null consultation included
embarrassment,26 social stigma,27 and, very likely, dissatisfaction
with the relationship with physicians and their ability to deal
with sexual health.16 Alexithymia could be considered another
possible factor explaining the latter point.28
Performers bought these drugs less frequently in official phar-
macies than patients, with a high risk of buying fake PDE5is.
Table 4. Analysis for diagnosis, drug dosage, reason for taking PDE5i, advice to take PDE5i, and place used to buy PDE5i by avanafil
users*
Avanafil user groups (N ¼ 778), n (%)
No (n ¼ 739) Yes (n ¼ 39)




Elevated cholesterol 25.6 32.2
Elevated blood pressure 29.8 28.2
Previous diagnosis of cardiac diseases 8.7 17.9
Depression 22.3 28.2
Anxiety symptoms 27.6 25.6
Renal diseases 3.7 0.0
Hepatic diseases 3.4 2.6
Question Category
Diagnosis No 86 (11.6) 2 (5.1)
No, but I have some problems 371 (50.2)† 10 (25.6)
Yes 282 (38.2)‡ 27 (69.2)
Drug dosage Low 179 (24.2) 12 (30.8)
Standard 413 (55.9) 17 (43.6)
High 147 (19.9) 10 (25.6)
Reason for taking PDE5i To improve strength and hardness of erection 423 (57.2) 24 (61.5)
To be more sure of myself 370 (50.1) 20 (51.3)
To gratify my partner 341 (46.1) 16 (41.0)
To feel more relaxed with my performance 286 (38.7) 16 (41.0)
To prevent performance anxiety 229 (31.0) 12 (30.8)
From curiosity, to try 52 (7.0) 2 (5.1)
Who decided to take or advised
taking PDE5i
Physician 485 (65.6)† 34 (87.2)
Myself 160 (21.7) 4 (10.3)
Pharmacist 52 (7.0) 1 (2.6)
Partner 36 (4.9) 0 (0.0)
Place usually used to buy
PDE5i
Pharmacy 594 (80.4) 34 (87.2)
Online pharmacy headquartered in my country 109 (14.7) 5 (12.8)
Online pharmacy headquartered abroad 62 (8.4) 2 (5.1)
Other (sex shop, disco, etc) 12 (1.6) 0 (0.0)
ED ¼ erectile dysfunction; PDE5i ¼ phosphodiesterase type 5 inhibitor.
*1-way analysis of variance or Kruskal-Wallis test was applied to detect differences.
†P < .05; ‡P < .0001 vs rest of sample.
20 Corona et alDriven by embarrassment or the desire for cheaper alternatives,
performers are often unaware they might be using fake products,
thus taking unnecessary health risks.29 Subjects who bypass
doctors often lose the opportunity to have not only ED but also
other comorbidities diagnosed; therefore, in this view, impotent
patients are paradoxically “lucky” for the unique chance to face
the ED-associated comorbidities.30 Our results are in line with a
European survey estimating that in Europe approximately 6
million men bypass the health care system to obtain a PDE5i.31 It
is crucial to discriminate how many performers have a subclinical
form of ED and how many truly sexually healthy subjects use
PDE5is recreationally to increase sexual performance.32,33Real-life experience seems to contradict the previous
assumption that PDE5is cannot improve erectile performance in
subjects with normal erection.34 Several studies have reported on
the use of PDE5i in young healthy men (mostly college students)
without any medical indication.18,35 Our European data confirm
the observation recently reported in Saudi Arabia, where 61.9%
of 370 PDE5i users were recreational performers and 31.8%
were patients with ED.36
Another interesting finding in our survey is that the highest
doses of on-demand PDE5i (avanafil 200 mg, sildenafil 100 mg,
tadalafil and vardenafil 20 mg) are much more frequentlySex Med 2018;6:15e23
Figure 2. Differences in International Index of Erectile Dysfunction
subdomain scores between avanafil users and non-users. *After
excluding subjects with severe erectile dysfunction. EF ¼ erectile
function; IS ¼ intercourse satisfaction; OF ¼ orgasmic function;
OS ¼ overall satisfaction; SD ¼ sexual desire.
Users of Phosphodiesterase Type 5 Inhibitors 21prescribed by physicians and obtained from an official pharmacy.
This can be explained by our additional evidence that the patients
were not only older but also had more comorbidities than per-
formers. Furthermore, physicians are more aware of the risks and
side effects of PDE5is than users and usually try to minimize the
risk of PDE5i failure from underdosing with consequent
depression. The expectation is that PDE5is might produce
negative effects on men’s mood after treatment failure at lower
doses. When patients are not satisfied because treatment did not
work, the distress is particularly severe.37 In the clinical setting,
this situation induces physicians to start treatment at the highest
available doses and then eventually to down-titrate the prescrip-
tion; in this way, bona fide, psychological, relational, and social
consequences of PDE5i failure from underdosing are limited.
When the highest doses are prescribed, the first choice should
favor the drug with the best ratio of efficacy to side effects.
The last point raised by our data concerns the subgroup of
subjects using avanafil, the unique 2nd-generation PDE5i
approved in Europe.38 This drug, characterized by a good bal-
ance between efficacy and tolerability profile,39 is much more
frequently prescribed by doctors than self-prescribed compared
with other PDE5is. This could suggest that there is still much
less awareness of the “users” on the availability of avanafil,14
likely because avanafil is the most recently marketed PDE5i.
Its “personality” as a “no worry drug” (no worry about
efficacy,40,41 no worry about time of onset,42 no worry about
safety14) is still unknown to most people compared with the
famous “blue pill” (sildenafil) or the “weekend pill” (tadalafil). In
the survey, patients using avanafil had significantly more severe
ED than patients using other PDE5is; this could explain why the
avanafil group reported a significantly lower IIEF-EF score
compared with other subjects.
The overall satisfaction with PDE5is was not high (w50%).
Very interestingly, this percentagewas similar among the 4 PDE5is.
This reflects the high discontinuation rate of this class of drug,17,43
demonstrating that there is still a need for a new taxonomy and a
renewedmultidisciplinary approach to ED and subclinical ED andSex Med 2018;6:15e23the psychological need of a pharmacologic sexual aid (the “users”),
which deserve social and medical attention.44 Accordingly, the
PDE5i-related satisfaction was higher when drugs were prescribed
by a physician. Previous studies have clearly documented that a
specific tailored therapy and adequate counseling can convert 30%
to 50% of the initial PDE5i non-responders to responders43e46
when offering a holistic, systemic approach to the dysfunction.47
The study has some limitations. In the analysis, we considered
only subjects who had on-demand use of PDE5i to make the
results more comparable and provide a picture of real-life atti-
tudes toward ED among European men; thus, we might have
lost important information from subjects who had long-term use
and were potentially more likely followed by physicians. Only
5% of participants declared using a 2nd-generation PDE5i;
further larger studies are required to confirm our preliminary
findings. Although the initial survey was started by more than
30,905 subjects, only a limited number satisfied the inclusion
criteria. Hence, selection bias might have influenced our results
and they cannot be immediately extended to the general popu-
lation. Further, the arbitrary division of subjects using PDE5i as
patients and performers cannot be generalized because there
might have been some overlap between these groups.
CONCLUSION
The present survey indicates that there are 2 different attitudes
toward ED and PDE5i use: the performers’ use of PDE5is
mainly for recreational use and without a medical prescription
and the patients’ use is with a formal ED diagnosis and a medical
prescription. No differences in efficacy were observed when the
1st generation of PDE5is was compared with the 2nd generation.
Avanafil represents a 2nd generation of PDE5i with the highest
tolerability profile; in this study, avanafil users were much more
frequently prescribed by doctors than self-prescribed. Overall,
PDE5i satisfaction was higher in patients who were prescribed by
a physician. Further studies would be advisable to better clarify
whether the 2nd generation of PDE5is could decrease the high
discontinuation rate reported with the 1st generation of PDE5is.
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